EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT).

Komajda, Michel; Weidinger, Franz; Kerneis, Mathieu; Cosentino, Francesco; Cremonesi, Alberto; Ferrari, Roberto; Kownator, Serge; Steg, Philippe Gabriel; Tavazzi, Luigi; Valgimigli, Marco; Szwed, Hanna; Majda, Wojciech; Olivari, Zoran; Van Belle, Eric; Shlyakhto, Evgeny Vladimirovich; Mintale, Iveta; Slapikas, Rimvydas; Rittger, Harald; Mendes, Miguel; Tsioufis, Constantinos; ... (2016). EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT). European Heart Journal, 37(2), pp. 152-160. Oxford University Press 10.1093/eurheartj/ehv437

Preview

Text ehv437.pdf - Published Version Available under License Publisher holds Copyright. Download (134kB) | Preview

AIMS

Chronic ischaemic cardiovascular disease (CICD) is a major cause of mortality and morbidity worldwide. The primary objective of the CICD-Pilot registry was to describe the clinical characteristics and management modalities across Europe in a broad spectrum of patients with CICD.

METHODS AND RESULTS

The CICD-Pilot registry is an international prospective observational longitudinal registry, conducted in 100 centres from 10 countries selected to reflect the diversity of health systems and care attitudes across Europe. From April 2013 to December 2014, 2420 consecutive CICD patients with non-ST-elevation acute coronary syndrome (n = 755) and chronic stable coronary artery disease (n = 1464), of whom 933 (63.7%) were planned for elective coronary intervention, or with peripheral artery disease (PAD) (n = 201), were enrolled (30.5% female patients). Mean age was 66.6 ± 10.9 years. The following risk factors were reported: smoking 54.6%, diabetes mellitus 29.2%, hypertension 82.6%, and hypercholesterolaemia 74.1%. Assessment of cardiac function was made in 69.5% and an exercise stress test in 21.2% during/within 1 year preceding admission. New stress imaging modalities were applied in a minority of patients. A marked increase was observed at discharge in the rate of prescription of angiotensin-converting enzyme-inhibitors/angiotensin receptor blockers (82.8%), beta-blockers (80.2%), statins (92.7%), aspirin (90.3%), and clopidogrel (66.8%). Marked differences in clinical profile and treatment modalities were observed across the four cohorts.

CONCLUSION

The CICD-Pilot registry suggests that implementation of guideline-recommended therapies has improved since the previous surveys but that important heterogeneity exists in the clinical profile and treatment modalities in the different cohorts of patients enrolled with a broad spectrum of CICDs.

Interest & Impact

Downloads

239 since deposited on 12 Apr 2017
34 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item